LXG6403 is a potent (IC50 = 1.3 µM) and selective (3.5x over LOXL2 and no inhibition of LOX1) lysyl oxidase (LOX) inhibitor. Active against LOX in multiple cell lines (IC50 <5 µM against MDA-MB-231, HCC143, Hs-578-T, and HCC1937). LXG6403 enhanced chemosensitivity of triple negative breast cancer cells to anthracycline, doxorubicin, cisplatin, and paclitaxel. It inhibited collagen crosslinking and deposition, increased doxorubicin penetration in cells and organoids, inhibited FAK signaling, and potentiated ROS/DNA damage axis in combination with cisplatin. LXG6403 was able to overcome doxorubicin resistance in the TM01278 TNBC PDX model.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
